Racial differences in clinical outcome after prostate cancer treatment

Methods in Molecular Biology

Volumn 472, Issue , 2009, Pages 455-466

  Fukagai, Takashi ^a   Namiki, Thomas ^a   Carlile, Robert G ^a   Namiki, Mikio ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical outcome; Hormonal therapy; Prostate cancer; Prostate specific antigen; PSA; Racial differences

Indexed keywords

ASIAN; CAUCASIAN; ETHNOLOGY; HUMAN; JAPAN; MALE; MORTALITY; PROSTATE TUMOR; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; JAPAN; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 58149478510     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-492-0_22     Document Type: Review

References (21)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007) Cancer statistics, 2007. CA Cancer J Clin. 57, 43-66.
2. Wynder, E.L., Fujita, Y., Harris, R.E., Hirayama, T., and Hiyama, T. (1991) Comparative epidemiology of cancer between the United States and Japan. Cancer. 67, 746-763.
3. Zaridze, D.G., Boyle, P., and Smans, M. (1984) International trends in prostatic cancer. Int J Cancer. 33, 223-230.
4. Oshima, A., Kuroishi, T., Tajima, K., (eds) (2004) Cancer Statistics in Japan 2004-Mortality, Incidence and Survival (In Japanese). Shinohara Publishers, Tokyo, Japan.
5. Thompson, I.M., Canby-Hagino, E., and Lucia, M.S. (2005) Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 97, 1236-1237.
6. Ito, K., Yamamoto, T., Ohi, M., Takechi, H., Kurokawa, K., and Suzuki, K.(2006) Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J Urol. 175, S477-478.
7. Eisenberger, M.A., Crawford, E.D., Wolf, M., Blumenstein, B., McLeod, D.G., Benson, R., Dorr, F.A., Benson, M., and Spaulding, J.T. (1994) Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 21, 613-619.
8. Thompson, I., Tangen, C., Tolcher, A., Crawford, E., Eisenberger, M., and Moinpour, C. (2001) Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 93, 219-225.
9. Pienta, K.J., Demers, R., Hoff, M., Kau, T.Y., Montie, J.E., and Severson, R.K. (1995) Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology. 45, 93-101.
10. McLeod, D.G., Schellhammer, P.F., Vogelzang, N.J. Soloway, M.S., Sharifi, R., Block, N.L., Venner, P.M., Patterson, A.L., Sarosdy, M.F., Kelley, R.P., and Kolvenbag, G.J. (1999) Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate. 40, 218-224.
11. Koff, S.G., Connelly, R.R., Bauer, J.J., McLeod, D.G., and Moul, J.W. (2002) Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. Prostate Cancer Prostatic Dis. 5, 152-158.
12. Young, J.L. Jr., Ries, L.G., and Pollack, E.S. (1984) Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst. 73, 341-352.
13. Fukagai, T., Namiki, S.T., Carlile, R., Yoshida, H., and Namiki, M. (2006) Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 97, 1190-1193.
14. Bostwick, D.G., Pacelli, A., and Lopez-Beltran, A. (1996) Molecular biology of prostatic intraepithelial neoplasia. Prostate. 29, 117-134.
15. Irvine, R.A., Yu, M.C., Ross, R.K., and Coetzee, G.A. (1995) The CAG and GGC microsatellites of the androgen receptor gene in linkage disequilibrium in men with prostate cancer. Cancer Res. 55, 1937-1940.
16. Bratt, O., Borg, A., Kristoffersson, U., Lundgren, R., Zhang, Q.X., and Olsson H. (1999) CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer. 81, 672-676.
17. Suzuki, H., Akakura, K., Komiya, A., Ueda, T., Imamoto, T., Furuya, Y., Ichikawa, T., Watanabe, M., Shiraishi, T., and Ito, H. (2002) CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate. 51, 219-224.
18. Sartor, O., Zheng, Q., and Eastham, J.A. (1999) Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 53, 378-380.
19. Jin, B., Beilin, J., Zajac, J., and Handelsman, D.J. (2000) Androgen receptor gene polymorphism and zonal volumes in Australian and Chinese men. J Androl. 21, 91-98.
20. Hsing, A.W., Gao, Y.T., Wu, G., Wang, X., Deng, J., Chen, Y.L., Sesterhenn, I.A., Mostofi, F.K., Benichou, J., and Chang, C. (2000) Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60, 5111-5116.
21. Ross, R.K., Bernstein, L., Lobo, R.A., Shimizu, H., Stanczyk, F.Z., Pike, M.C., and Henderson, B.E. (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339, 887-889.